Eloxx Pharmaceuticals, Inc. Common Stock (ELOX)
NASDAQ
Closed
Oct 19, 2026
Day's Range
12.4952 wk Range
0.00110Overview - ELOX - Eloxx Pharmaceuticals, Inc. Common Stock
Key Statistics
Valuation
Enterprise Value
2.46M
P/E (Trailing)
‪3.70‬
P/E (Forward)
‪-18.35‬
PEG Ratio
‪-0.07‬
Price / Book
‪1.13‬
EV / EBITDA
‪-0.39‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-113.75%‬
Return on Equity
‪50.34%‬
Ownership
Shares Outstanding
3.43M
Float
931.13K
Short % of Shares Outstanding
‪1.48%‬
Held by Insiders
‪19.06%‬
Held by Institutions
‪73.76%‬
Price stats
Beta
‪-171,332.88‬
50-Day Avg
‪16.37‬
200-Day Avg
‪14.86‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
4 analysts
Average price target
‪$ 40.33‬Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - ELOX - Eloxx Pharmaceuticals, Inc. Common Stock
Peers - ELOX - Eloxx Pharmaceuticals, Inc. Common Stock
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- ELOXNASDAQEloxx Pharmaceuticals, Inc. Common Stock52.59MMarket Cap+99.99%52-week change3.70P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQArgenx SE51.51BMarket Cap-3.70%52-week change31.22P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.31.02BMarket Cap-111.89%52-week change39.09P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share22.03BMarket Cap-23.08%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.82BMarket Cap+8.90%52-week change17.26P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.97BMarket Cap+15.27%52-week change-17.56P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.10.58BMarket Cap+1.57%52-week change147.76P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - ELOX - Eloxx Pharmaceuticals, Inc. Common Stock
About
Eloxx Pharmaceuticals, Inc. Common Stock represents equity in Eloxx Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing novel small-molecule medicines that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations. The company’s current pipeline…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
